{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:58:24Z","timestamp":1785517104930,"version":"3.56.0"},"reference-count":11,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nephron"],"abstract":"<jats:p>Background: Monoclonal gammopathy of renal significance (MGRS) is a rare group of renal disorders caused by monoclonal immunoglobulins from non-malignant B-cell or plasma cell clones, with distinct amyloid (MGRS-A) and non-amyloid (MGRS-NA) subtypes. Although these are often grouped together, whether they share similar clinical phenotypes and outcomes is uncertain. We therefore examined similarities and differences between these subtypes in a contemporary real-world cohort. Methods: We performed a single-centre retrospective evaluation of 17 biopsy-confirmed MGRS patients (10 MGRS-A, 7 MGRS-NA). Baseline parameters, treatment exposure, renal and haematologic responses, survival, and relapse were analysed descriptively with exploratory subgroup comparisons. Results: MGRS-NA patients presented with significantly worse baseline renal function (median estimated glomerular filtration rate 18.0 mL\/min\/1.73 m2 vs. 49.0 mL\/min\/1.73 m2 in MGRS-A, p &lt; 0.05) and progressed faster to dialysis (p &lt; 0.01). Haematologic responses (\u2265VGPR) were achieved in 57.1% of MGRS-NA and 50% of MGRS-A patients, but these did not significantly correlate with renal improvement. Survival was similar between groups, with deaths in 28.6% of MGRS-NA and 20% of MGRS-A. Relapse occurred in 47.1% of patients, with median times of 51 months in MGRS-NA and 69 months in MGRS-A. Treatment, primarily bortezomib-based chemotherapy, was associated with toxicities (94.1%), yet renal responses remained limited. Conclusion: The findings highlight the poor prognosis and rapid renal decline in MGRS-NA. We highlight the need for early diagnosis and an integrated renal-haematologic service to improve outcomes in this rare population.<\/jats:p>","DOI":"10.1159\/000553058","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:28:19Z","timestamp":1781454499000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Outcomes of Patients with Monoclonal Gammopathy of Renal Significance"],"prefix":"10.1159","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0808-8779","authenticated-orcid":false,"given":"Gerard","family":"Gurumurthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Fielding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Crea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-7878","authenticated-orcid":false,"given":"Durga A.K.","family":"Kanigicherla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-445304"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000201"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23412"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19956"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.24.111"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-570010"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26566"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15987"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17052"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019031914"}],"container-title":["Nephron"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000553058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:00:57Z","timestamp":1785513657000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000553058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":11,"URL":"https:\/\/doi.org\/10.1159\/000553058","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.32664849","asserted-by":"subject"}]},"ISSN":["1660-8151","2235-3186"],"issn-type":[{"value":"1660-8151","type":"print"},{"value":"2235-3186","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]}}}